u/Emotional-Breath-838

I take a look at my irresponsible warrant position and see someone paid $3.15 per warrant after market and I’m not hyped. It makes sense if the warrants are in the money at $11.50 and you still have the theta (time value) of 10 more months before they’re due.

I look at the market cap for DRTS and I’m not hyped. Yeah, it’s a One Billion Dollar Market Cap company which is mind boggling given where it languished just 9 months ago.

I look at Pristine’s subreddit getting 5,000+ visitors a week and I’m not hyped. I was here when it was around 500 and he runs an amazing place for information so it should be higher.

And then I look at ASCO and I get hyped.

Really hyped.

The five year survival rate of Pancreatic Cancer has barely moved since the 1990’s and sits at 13%.

The specific type of pancreatic cancer that Alpha Tau Medical is currently targeting in its clinical trials—including the ACAPELLA study in Europe and the IMPACT trial in the U.S.—is Pancreatic Ductal Adenocarcinoma (PDAC), specifically in its locally advanced (inoperable) stage.

PDAC is the form that accounts for more than 90% of all pancreatic cancer diagnoses. It is widely considered one of the most lethal and aggressive malignancies due to its rapid local invasion, particularly when it infiltrates critical vascular structures, rendering it surgically unresectable.

In the context of Alpha Tau's trials, they are specifically focusing on this "locally advanced" population—patients whose tumors have not yet metastasized to distant organs but are too integrated into major blood vessels to be safely removed via traditional surgery, leaving them with few standard-of-care options.

AND THAT LAST LINE IS WHERE I GO HYPE.

I have been following Alpha Tau closely for a long time but I missed something obvious. There is NO standard of care for recurring GBM. The standard of care for PDAC sucks.

What the ASCO presentation has the potential to do is make clear what I missed: Alpha Tau Medical is positioning their DaRT platform to be the standard of care across two of the most deadly and untreatable forms of cancer.

Yes, we need survivability numbers. And yes we need more and more cases. And yes we need safety readouts and FDA approval and so many things that can’t be overlooked as real risks.

But when you step back and stop counting the money from your brilliant investment, you begin to see that the ability to insert high-LET radiation into inoperable tumors via an easy to master platform is a game changing approach to tumors where nothing else exists.

ASCO is the coming out party for the new addition to the standard of care for PDAC and the realization in the biotech world that DaRTs will be the only standard of care for recurring GBM.

If you are not hyped, I want you to take a breath and reread that last paragraph. Those who understand the implications will make a fortune.

We are early. We are supporting a powerful platform run by a brilliant team with far, far too many patients in areas where there is no competition and, sadly, so little hope.

And after ASCO, the entire industry will know it as well.

I am long on DRTS.
I am irresponsibly long on DRTSW.
I am hyped.

One important point for DRTS shareholders to understand is that Alpha Tau Medical should not be analyzed exactly like a standard oncology drug company.

Alpha DaRT is a medical device / radiation therapy platform. That makes its regulatory path different from a traditional drug that moves through the classic Phase 1, Phase 2, Phase 3, NDA/BLA framework.

In the U.S., the relevant framework is the medical device pathway: IDE studies and, for a high-risk device, PMA approval. A pivotal device study can serve the same broad purpose as a Phase 3 drug trial — meaning it can support approval — but the design, size, endpoints, and cost structure can be very different.

That distinction matters. A Phase 3 oncology drug trial often enrolls hundreds or thousands of patients, is frequently randomized, may run globally, and can cost tens or hundreds of millions of dollars. A pivotal device study can be smaller, more targeted, and sometimes single-arm if the clinical setting and prior data justify it.

Alpha Tau’s recurrent cutaneous squamous cell carcinoma program is the clearest example. Its ReSTART study is a multi-center, single-arm, open-label pivotal study with roughly 88 patients. That is a serious approval-supporting study, but it is not the same thing as a giant randomized oncology drug Phase 3 trial.

This does not mean approval is easy. It also does not mean the trials are cheap. Device studies still require clinical sites, trained investigators, patient monitoring, imaging review, safety tracking, data systems, statistics, manufacturing controls, quality systems, and regulatory work. A pivotal device trial can absolutely cost millions of dollars, and some can cost tens of millions depending on the indication, complexity, number of sites, follow-up, and endpoints.

Skin cancer is the most advanced U.S. program and is already in pivotal territory. Other areas, such as pancreatic cancer, GBM, prostate cancer, and additional solid tumors, are earlier-stage pilot or feasibility programs. Those studies are designed to answer practical questions: can Alpha DaRT be placed safely, can the procedure be done reliably, is there early evidence of activity, what safety issues appear, and what kind of future pivotal trial would make sense?

That approach is different from a drug company trying to run several large Phase 3 trials at once. Alpha Tau can test the platform across multiple tumor types with smaller studies, then decide which indications justify larger pivotal work.

The same general distinction applies outside the U.S. In Europe, medical devices are reviewed through the CE Mark / MDR framework, focused on safety, performance, clinical evidence, risk management, manufacturing quality, and post-market surveillance. In Japan, Alpha Tau has already received Shonin approval through the country’s medical device approval pathway for a defined indication. None of this guarantees approval in other markets, but it reinforces that Alpha DaRT is being evaluated as a regulated medical device, not through the ordinary drug-approval model.

For investors, this is not just a technical regulatory detail. It affects trial costs, timelines, capital needs, dilution risk, and the odds of reaching a first commercial approval. A device company that may be able to support approval with a focused pivotal study is in a different position from a biotech that needs multiple huge randomized drug trials before revenue.

The device pathway may give Alpha Tau a more targeted and capital-efficient route to first approval if the data are strong.

The future pivotal studies, especially in deeper tumors like pancreatic cancer, GBM, or prostate cancer, may still be complex, expensive, and indication-specific. The company still has to prove durability, safety, procedural reliability, manufacturing execution, reimbursement, physician adoption, and commercial readiness.

TL;DR: Alpha Tau should be understood as a medical device / radiation oncology platform company. Its pivotal studies may function as approval-enabling trials, but they are not the same as traditional drug Phase 3 trials. That distinction matters because it may mean smaller studies, more regulatory flexibility, lower capital intensity, and a more efficient path to first approval — while still leaving plenty of real clinical and execution risk.

Tens of thousands of oncologists, researchers, and life science executives will converge on Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting. Few conferences carry as much weight in oncology. ASCO is where the field evaluates emerging data and identifies therapies poised to shift the standard of care.

This year’s ASCO meeting runs May 29–June 2 at McCormick Place. Among the presenting companies is Alpha Tau Medical (Nasdaq: DRTS), which will share new data on Alpha DaRT in advanced pancreatic ductal adenocarcinoma (PDAC)—a disease that remains among oncology’s most persistent challenges.

With nearly 50,000 members globally, ASCO represents the clinicians, investigators, regulators, and guideline writers who directly shape cancer treatment. The 2026 program features over 3,400 abstracts across 200+ sessions. Selection relies on blinded peer review; expert committees assess methodological rigor, clinical relevance, and data maturity. Acceptance does not guarantee efficacy, but it does indicate the findings meet the society’s threshold for scientific discussion. For emerging developers, that validation often determines whether a program attracts partnership interest, advances to larger trials, or gains traction with treating physicians.

Alpha Tau’s accepted abstract, “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer,” presents a pooled analysis of 58 patients. All participants had locally advanced or metastatic PDAC and received intratumoral Alpha DaRT via endoscopic ultrasound (EUS) guidance.

Pancreatic cancer’s therapeutic landscape sucks. The five-year survival rate remains approximately 13% overall, with locally advanced disease at roughly 15% and metastatic disease near 3%. Once the disease disseminates, median survival is typically measured in months. There is a desperate need for something new and effective.

This ASCO presentation follows earlier data disclosures at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco and Digestive Disease Week. Repeated acceptance at major GI-focused meetings signals sustained clinical interest rather than an isolated data drop. Alpha Tau is concurrently advancing its pancreatic pipeline, including the IMPACT and ACAPELLA trials, and recently initiated its U.S. multi-center program with first-patient dosing. The ASCO appearance fits into a deliberate clinical development strategy rather than a standalone marketing effort.

The full abstract will be released on May 21, 2026, at 5:00 PM ET.

Conventional brachytherapy, as Grigribs has noted ad nauseam, has been around for decades. And for many cancers — prostate, cervical, breast, certain skin lesions — it works very well. But it has well-documented limits: it places a sealed source (seeds, wires, or capsules) inside or next to the tumor, where it emits photons or beta particles. Both are low-LET radiation. The dose falls off gradually with distance, depends heavily on tumor oxygenation to generate the free radicals that damage DNA, and produces damage that cells can largely repair. That's why conventional brachytherapy struggles with hypoxic, radioresistant, and recurrent tumors — exactly the cases Alpha Tau is going after.

Grigribs hears "radiation in tumors → must be conventional brachytherapy," plugs his ears, and looks no further. Here's what he misses.

DaRT is a next-generation form of brachytherapy. The seed is still implanted in or next to the tumor — but it's loaded with Ra-224, and the therapeutic effect comes not from the seed itself but from short-lived daughter atoms that recoil off the seed surface and diffuse a few millimeters into the surrounding tissue. The alpha particles released have very short range (~50–90 microns each, which is why Grigribs's facility-contamination panic is silly) and extremely high LET, producing dense, clustered double-strand DNA breaks that are largely irreparable and substantially less oxygen-dependent. Same general approach as conventional brachytherapy. Better mousetrap.

How do we know Grigribs is full of it on the physics?

The biggest tell is that he says Ra-224 "undergoes fission." It doesn't. It undergoes alpha decay. Fission is a heavy nucleus splitting into two large fragments — what happens inside a reactor. Alpha decay is the emission of a He-4 nucleus. Completely different nuclear processes. Anyone who works seriously with radioisotopes knows this distinction cold. It's the kind of error a layperson makes after skimming a Wikipedia paragraph, not something a practicing radiation oncologist would write.

He also oversimplifies the decay chain to scare investors. Yes, Rn-220 (thoron) is a gas — but its half-life is 55.6 seconds, which is precisely why Alpha Tau built DaRT around the Ra-224 chain rather than the Ra-226 chain (whose Rn-222 daughter has a 3.8-day half-life and is the actually dangerous radon — the kind in your basement). Rn-220 decays to solid Po-216 before it can travel meaningfully, and the therapeutic workhorse of the chain is Pb-212, a solid metal with a 10.6-hour half-life that stays put in tissue. The "gaseous contamination of the OR" framing ignores both the physics and the biodistribution work Alpha Tau has published showing how little of anything escapes the treatment volume.

Grigribs will fearmonger further about strict safety measures for transport and storage. This is true — and it's also true of every therapeutic radionuclide on the market: I-125 seeds, Lu-177, Y-90 microspheres, Ra-223. He's framing a baseline regulatory requirement as if it were a unique DaRT liability.

On "the six oncologists I work with aren't interested":

This is the only argument that isn't flatly wrong, but it's softer than he's presenting it. DaRT isn't FDA-approved in its lead indications yet, so of course community oncologists aren't using it — they can't. The relevant benchmark before pivotal data and a label is investigator interest at trial sites and KOLs in the targeted indications, not the enthusiasm of six oncologists at a community practice. And the fact that those oncologists "regularly perform other forms of brachytherapy" actually cuts the other way: the procedural skill and infrastructure already exist in their clinics, lowering the adoption barrier when DaRT lands. If DaRT becomes standard of care in indications like recurrent GBM or unresectable pancreatic cancer — where current options offer dismal outcomes — those oncologists won't be in a position to ignore it.

TL;DR

DaRT is a next-generation form of brachytherapy. Same general approach as conventional brachytherapy — radioactive source implanted at the tumor — but with extremely high-LET alpha radiation whose energy is deposited within microns of each decay event, producing clustered DNA damage that cells largely cannot repair, with minimal dose to tissue outside the millimeter-scale treatment volume. Conventional brachytherapy uses low-LET beta or gamma radiation that is repairable, oxygen-dependent, and falls off more gradually — which is why DaRT can address hypoxic and radioresistant tumors that conventional brachytherapy struggles with.

DaRT's operator and clinic radiation profile compares favorably to conventional gamma brachytherapy: alpha particles are stopped by the seed surface and skin, the gamma component of the Ra-224 decay chain is modest, and Rn-220's 55-second half-life confines any daughter diffusion to a few millimeters of tissue. Standard radiopharmaceutical handling protocols apply, as with any therapeutic isotope — but the specific concerns about OR contamination or gaseous escape Grigribs raises aren't supported by the underlying physics or the clinical handling experience accumulated to date.

Pristine ran a phenomenal Hoodie and hat giveaway based on guessing the DRTS stock price at the end of September.

(If you haven’t made your guess yet, you’re brilliant because most of us were guessing before two CRs in rGBM… go place your bet ASAP)

I know the contest is still open but it would be really cool if one of you math wizards could go through the post and average out the expected price of DRTS at the end of September.

It’s likely a bit conservative given we didn’t know DRTS destroyed two recurring brain tumors but it would still be interesting “wisdom of the crowd” stuff.

Fun game if you’re new to Alpha Tau and doing deep dive due diligence: as you go through the reported cases, how many likely Abscopal effects can you find?

What’s Abscopal?

The Abscopal effect is the holy grail: it’s when you treat a local tumor and find out that the body is destroying distant, unrelated tumors as a result.

Has it happened with Alpha Tau?

Sort of. It’s been reported several times but it’s never been a targeted endpoint for any of the studies.

Why might it be real for DRTS?

Pure speculation is that the destroyed tumor is somehow training the immunity system how to respond to other tumors.

Why doesn’t it happen every time?

Alpha Tau’s results are almost never front line cases. Almost always the patients they get have blown immunity systems from multiple chemo sessions or more traditional full body radiation. Those patients are out of options and Alpha Tau results are, remarkably, coming after all else has failed.

One of the things we are hoping to see before too long is what happens if you treat with DRTS before the patient has been through so many other procedures.

If you find some abscopal effects in your research, share them with us! They’re out there and they’re a very bullish signal.

Take a look and see if it's worth an upvote. Thanks!

https://www.reddit.com/r/stocks/comments/1tc00tp/follow_up_alpha_tau_medical_drts_huge_win_vs_rgbm/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button

Original post was here: https://www.reddit.com/r/stocks/comments/1t9ydga/drts_conference_call_today_for_rgbm_biotech/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button

This is a quick follow up since many don't track biotech and many don't subscribe to r/DRTS_Stock

As promised, we had a call with the CEO, CFO, CMO and the Oncologist that performed the three Ohio cases, all against inoperable recurring GBM.

The results were stunning and, quite frankly, better than anyone could have expected.

When analyzing brain cancer trial data, you're looking for results against the RANO 2.0 global standard which categorizes results based on:

Progressive Disease: it got worse

Disease Control: the tumor shrank but less than 50%

Partial Response: the tumor shrank more than 50%

Complete Response: this is the ultimate goal when the MRI shows that there is no trace of the lesion.

Alpha Tau announced that they achieved two (2) Complete Responses. The third was Disease Control with a 30% reduction in the tumor. The side effects were minimal, expected and ended quickly.

Why am I posting this on r/stocks? Several reasons...

1. Everyone knows someone that has lost someone to cancer

2. There is NO standard of care in rGBM. They typically tell you to get your things in order and say goodbye to everyone.

3. The physics based approach that Alpha Tau uses has now been validated by PMDA (Japan's FDA) certification and their 100% DCR against nearly 100 human (not rats) cases of Pancreatic cancer and, as of this conference call, by two CRs against the most horrible rGBM.

4. The stock moved up on the news obviously, but I'm certain it still has room to run and here's why: The market cap has only now crossed the $1B mark. That means that institutional investors can finally dip their massive toes into what was only retail shareholders tiny pond.

5. The same day Alpha Tau announced they were going to share the rGBM results, they also announced that they completed the full testing against skin cancer and are prepared to close the first FDA certification. Given that the remaining rGBM cases (7) in New York City can be completed before year end, a pivotal study could easily be accelerated under the current FDA because there is NO current standard of care for rGBM and Alpha Tau has such limited side effects that it should be fast tracked.

So, you have a company with a unique physics (targeted radiation directly into the worst forms of solid tumors) based platform filling a critical need with certification in Japan, a set of great results from their team up with Keytruda, Merck's $30B baby, and soon to be standard of care all alone for rGBM. Any idea what they can charge for brain cancer?

The "waters" are chummed up for M&A since nearly all of the big pharmas are facing a patent cliff and that means that acquisitions are through the roof. Typical radiology acquisitions go for $4B which would mean that Alpha Tau has roughly a 4X shot of going up on M&A news if they don't stick around and commercialize their 100+ patents themselves.

I am long. I am bullish. I am encouraging you to go to r/DRTS_Stock to gain more insights on how Alpha Tau is handling the radiation and forward logistics and the very powerful team running this for the past ~7 years. Most of all, I'm encouraging you to take a look and see whether you want to front run the institutions and algorithms and etfs and indexes that will almost certainly come once this platform is in place globally.

NFA/DYOR

I have no idea what’s in Ft. Knox and I don’t have a political dog in this race.

We were told a new Ft. Knox assessment of gold holdings would be forthcoming and then it all went quiet.

I am assuming that there is a serious economic impact if they assess too little gold, too much gold, no gold, etc.

What are those economic scenarios and is it possible that we don’t see the gold holdings because of that impact?

https://preview.redd.it/ujcuxkfqwq0h1.png?width=933&format=png&auto=webp&s=baec23b127bb2579ceba25be9dd55c0ff4350bcd

I got DBMF as a hedge for days like these. And it still went down. Credit goes to PIT which stayed up on a very down day. It's performance has been solid for a commodity ETF (a bit better than FMTM, a bit worse than SGRT) but you learn what you have on days like today.

https://preview.redd.it/q32qqq4udj0h1.png?width=2316&format=png&auto=webp&s=ffffe80b5500aa0edef717a464536cd7ff9cb94a

Almost every time over the past year, when I would share due diligence with other subs on Reddit, I would get accused of Pump & Dump.

Why on Earth would anyone sell a stock that is on the verge of FDA approval and becoming the standard of care for rGBM?

Alpha Tau Medical [nasdaq: DRTS] is going to host a conference call Monday AM regarding the preliminary results from their recurrent GBM (inoperable brain cancer) trial.

The shareholders didn't expect this but are taking it as potentially very good news because the remaining cases (they've moved from Ohio to NYC) are still scheduled. The question is, "How good is the news?" We'll have to attend the call to find out so I put together a cheat sheet for those that are wondering what to listen for when considering rGBM progress.

As you're aware, this is not a drug company. This is a medical device company. They use physics (alpha radiation delivered in nanometer level targeting directly into solid tumors) rather than chemistry. If their hyper-local physics don't destroy nearby tissue or the immunity system, then any positive results they get mean that the DaRTs can be used in conjunction with other therapies. That's a very good thing.

More on the rGBM below but for those that haven't heard of Alpha Tau (DRTS), here's a quick primer...

They have already received PMDA (Japan's FDA) certification for Head & Neck cancers, so it's a real platform that provides oncologists with a new tool.

They have been on an insane hot streak since receiving PMDA.

Alpha Tau got approval from the FDA for testing with Keytruda, Merck's $30B baby, and quickly demonstrated a massive (2x, 3x) efficacy increase.

They compiled the results from their Pancreatic Cancer trials which showed an extremely impressive 100% DCR (disease control response.) It is believed they have completed nearly 100 cases of late, late stage PanC and have now been approved for new trials in Japan, France, Italy and Canada.

The FDA has granted five modules for Alpha Tau which includes trials for brain, pancreas, prostate and other solid cancers, either alone or in conjunction with other therapies.

Over the past year, they've run up a gaudy 200%+ and still maintain a market cap of only $750M.

And, because it's rGBM, there is a possibility that the recurring GBM cancer initial trial data changes everything.

THERE ARE NO GOOD TREATMENTS FOR rGBM.

When a neuro-oncologist faces a recurrent GBM case, they are not choosing between good and better options — there is no standard of care, and all available treatments are considered non-curative. They are managing a patient who has already survived longer than most, whose tumor has now outsmarted surgery, radiation, and chemotherapy, and who is almost certainly going to die from this disease. After first-line therapy fails, median progression-free survival is 1.5 to 6 months and median overall survival is 2 to 9 months. The oncologist's toolkit at this point — more chemotherapy, re-irradiation, or bevacizumab — may slow things briefly but changes nothing fundamental. Recurrent GBM is widely considered one of the most disappointing fields in oncology, where decades of research have yielded no meaningful survival benefit. The honest conversation an oncologist has with an rGBM patient is not about getting better. It is about how much time remains, and how to spend it.

Back to Alpha Tau and the hope for hope where none exists...

There have been 3 cases in the 10 person trial so far; all out of Ohio. The remaining 7 will be done in New York City starting this month. We aren't looking for survivability duration. What we're looking for is:

Safety: The procedure (outpatient typically) can be done without causing harm to the brain or immunity system. You'll know it's solid if the patient walks out on their own power within 48 hours of the procedure and follow up testing.

Coverage: How much of the tumor was hit with the targeted radiation? We're looking for 80%+ coverage of the tumor. Hit the tumor hard with high-LET Alpha Radiation.

And we're expecting that the MRI's taken of these initial patients have shown something worth sharing with shareholders but you'll need to understand how to evaluate initial results.

Initial results = RANO

When you're dealing with rGBM, there is a standardized way of understanding trial results called RANO 2.0. RANO is Response Assessment of Neuro-Oncology and it is a standard globally that looks at an MRI taken after treatment to determine whether the tumor has grown, shrunk, how much and whether continued treatment with corticosteroids is needed, etc.

RANO terms to listen for on the conference call:

Stable Disease (SD) No new lesions. No increase in corticosteroid use. Clinical status is seen as stable. If the tumor shrinks but by less than 50%, or stays roughly the same size, you have stable disease. In a cancer as aggressive as rGBM, halting progression is clinically meaningful — but of the four outcomes discussed here, SD is the most modest signal for investors.

Partial Response (PR) The tumor has shrunk by at least 50%. This is incredibly rare and would be considered fantastic news. Even one of the three patients achieving a PR would be a reset for DRTS because it means that there is (FINALLY) a potential way of seriously shrinking the GBM tumor.

Complete Response (CR) A complete obliteration of the tumor. Such a result would be a landmark in rGBM oncology. Nobody should expect this but everyone should understand that this is the dream. The whole world of oncology changes overnight if there is a CR on any one of the three patients.

Abscopal Effect This is a mythological creature. Remember that Alpha Tau's DaRT therapy is a local treatment, meaning that they're inserting the radium-covered darts directly inside a single tumor. There have been, over the past few years, a few odd cases where oncologists noticed the strange reality that distant, untreated tumors responded to the local DaRT treatment. The current thinking is that local tumor destruction releases tumor antigens that prime the immune system to recognize and attack the same cancer elsewhere in the body. Again, nobody expects to see abscopal effects on the first three patients but if you hear it on the call, you know what they're talking about.

So, you have a stock that is up 200% over the past year, it's not a typical biotech stock because it's a device, it has achieved cert in Japan, it has shown phenomenal initial results with Pancreatic cancer and it's on the verge of announcing something positive in recurring GBM. The market cap is $750M and typical M&A in the radiotherapy space goes for $4B.

Hit me up with any questions. Not a medical professional. Not financial advice. And yes, I'm irresponsibly long on this stock because fck cancer.

Alpha Tau Medical [nasdaq: DRTS] is going to host a conference call Monday AM regarding the preliminary results from their recurrent GBM (inoperable brain cancer) trial. If you're interested, the following is what you need to know.

This is not a drug company. This is a medical device company. They use physics (alpha radiation delivered in nanometer level targeting directly into solid tumors) rather than chemistry.

They have already received PMDA (Japan's FDA) certification for Head & Neck cancers, so it's a real platform that provides oncologists with a new tool.

They have been on an insane hot streak since receiving PMDA.

Alpha Tau got approval from the FDA for testing with Keytruda, Merck's $30B baby, and quickly demonstrated a massive (2x, 3x) efficacy increase.

They compiled the results from their Pancreatic Cancer trials which showed an extremely impressive 100% DCR (disease control response.) It is believed they have completed nearly 100 cases of late, late stage PanC and have now been approved for new trials in Japan, France, Italy and Canada.

The FDA has granted five modules for Alpha Tau which includes trials for brain, pancreas, prostate and other solid cancers, either alone or in conjunction with other therapies.

Over the past year, they've run up a gaudy 200%+ and still maintain a market cap of only $750M. There is a possibility that the recurring GBM cancer data changes everything.

THERE ARE NO GOOD TREATMENTS FOR rGBM.

There have been 3 cases in the 10 person trial so far; all out of Ohio. The remaining 7 will be done in New York City starting this month. We aren't looking for survivability duration. What we're looking for is:

Safety: The procedure (outpatient typically) can be done without causing harm to the brain or immunity system. You'll know it's solid if the patient walks out on their own power within 48 hours of the procedure and follow up testing.

Coverage: How much of the tumor was hit with the targeted radiation? We're looking for 80%+ coverage of the tumor. Hit the tumor hard with high-LET Alpha Radiation.

And we're expecting that the MRI's taken of these initial patients have shown something worth sharing with shareholders but you'll need to understand how to evaluate initial results.

Initial results = RANO

When you're dealing with rGBM, there is a standardized way of understanding trial results called RANO 2.0. RANO is Response Assessment of Neuro-Oncology and it is a standard globally that looks at an MRI taken after treatment to determine whether the tumor has grown, shrunk, how much and whether continued treatment with corticosteroids is needed, etc.

RANO terms to listen for on the conference call:

Stable Disease (SD)

No new lesions. No increase in corticoid steroid use. Clinical status is seen as stable. If the tumor shrinks up to 50%, you have a stable disease. This is considered very good news and means that the progression-free survival endpoints may be possible.

Partial Response (PR)

The tumor has shrunk more than 50%. This is incredibly rare and would be considered fantastic news. Even one of the three patients achieving a PR would be a reset for DRTS because it means that there is (FINALLY) a potential way of seriously shrinking the GBM tumor.

Complete Response (CR)

A complete obliteration of the tumor. Such a result would be a landmark in rGBM oncology. Nobody should expect this but everyone should understand that this is the dream. The whole world of oncology changes overnight if there is a CR on any one of the three patients.

Abscopal Effect

This is a mythological creature. Remember that Alpha Tau's DaRTs therapy is a local treatment, meaning that they're inserting the radium covered darts directly inside a single tumor. There have been, over the past few years, a few odd cases where oncologists noticed the strange reality that distant, untreated tumors responded to the local DaRTs. I won't profess to understand how Abscopal works but the way it was dumbed it down for me was to say that the body's immunity system "learns" how to fight tumors once the first tumor is obliterated. Again, nobody expects to see abscopal effects on the first three patients but if you hear it on the call, you know what they're talking about.

So, you have a stock that is up 200% over the past year, it's not a typical biotech stock because it's a device, it has achieved cert in Japan, it has shown phenomenal initial results with Pancreatic cancer and it's on the verge of announcing something positive in recurring GBM. The market cap is $750M and typical M&A in the radiotherapy space goes for $4B.

Hit me up with any questions. Not a medical professional. Not financial advice. And yes, I'm irresponsibly long on this stock because fck cancer.